Barclays Upgrades Sagimet Biosciences to Overweight, Raises Price Target to $18
Benzinga Newsdesk 1 month ago
NewsUpgradesAnalyst RatingsPrice Target
Barclays analyst Eliana Merle upgrades Sagimet Biosciences (NASDAQ:SGMT) from Equal-Weight to Overweight and raises the price target from $8 to $18.
Barclays analyst Eliana Merle upgrades Sagimet Biosciences (NASDAQ:SGMT) from Equal-Weight to Overweight and raises the price target from $8 to $18.